Andere talen Bristol-Myers Squibb Company Borsa Italiana

Aandelen

4BMY

US1101221083

Geschatte realtime Tradegate Andere beurzen 19:45:23 18-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
37,91 ^EUR	-2,68%		+0,45%	-16,06%

17:48	Immunocore randomiseert eerste patiënt in fase 3-studie van combinatiebehandeling voor huidmelanoom	MT
13/06	Augtyro van Bristol-Myers Squibb krijgt versnelde goedkeuring van FDA voor behandeling van vaste tumoren	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Immunocore Randomizes First Patient in Phase 3 Trial of Cutaneous Melanoma Combination Treatment	17:48
Bristol Myers Squibb Keeps Quarterly Dividend at $0.60 a Share, Payable Aug. 1 to Shareholders of Record July 5	15:41
Bristol Myers : dividendes décidés par le conseil	13:26
Bristol Myers Squibb Announces Dividend	13:00
Bristol Myers Squibb Declares A Quarterly Dividend, Payable on August 1, 2024	12:59
Bristol Myers : approbation de la FDA pour un traitement	14/06
Bristol-Myers Squibb's Augtyro Gets FDA Accelerated Approval for Treatment of Solid Tumors	13/06
Bristol Myers Squibb's Augtyro Gets FDA Accelerated Approval	13/06
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors	13/06
Bristol Myers Squibb Announces U.S. Food and Drug Administration Approves Augtyro (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors	13/06
Evotec to Receive $20 Million Under Neuroscience Partnership with Bristol Myers Squibb	12/06
Evotec Gets $20 Million Milestone Payment in Neurodegenerative Disease Collaboration With Bristol Myers Squibb	12/06
Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb	12/06
Evotec erhält Forschungszahlung von 20 Mio USD von Myers Squibb	12/06
ABL Bio, BMS Collaborate on Gastric Cancer Treatment Trial	10/06
Geron shares surge after U.S. FDA approves blood disorder drug	07/06
I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers	05/06
Bristol Myers Squibb Announces Opdivo Plus Yervoy Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma	05/06
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers	05/06
Bristol-Myers Squibb Says Opdivo Plus Yervoy Therapy Improves Survival of Liver Cancer Patients	04/06

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Headlines

Bristol-Myers CEO zegt dat het bedrijf in overgang is

09 januari 2024 om 19:06 uur